ArticleTrials2021

SAVER: sodium valproate for the epigenetic reprogramming of high-risk oral epithelial dysplasia-a phase II randomised control trial study protocol.

Caroline McCarthy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.